Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Standard Medicines
Drugs
Locations
Clinical Specialty
1641-1660 of 1,782 trials

Durvalumab for Non-Surgical Non-Small Cell Lung Cancer

We are studying the safety and effectiveness of the immunotherapy durvalumab followed by radiation in patients with early stage or locally advanced non-small cell lung cancer. This trial aims to find out if this treatment approach can help those who cannot have surgery.

Non-Small Cell Lung Cancer1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Antibiotics in Children with Brain Tumors

We are studying how different antibiotics move into the cerebrospinal fluid of children with malignant brain tumors. This research may help improve treatment for infections in these patients.

Brain Tumors>2 yearsSafety phase (I)No PlaceboStandard MedicinesInfectious DiseasesOncologyPediatrics

Levosimendan for Faster Recovery from Ventilation

We are studying whether levosimendan can help critically ill patients wean off invasive ventilation more quickly. The trial also examines patient experiences and healthcare needs during recovery.

Difficulty Stopping Mechanical Ventilation≤3 monthsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyPulmonology

Advanced Non-Small Cell Lung Cancer: Cemiplimab Treatment Study

We are investigating whether treatment decisions based on blood tests for tumor DNA improve outcomes for patients with advanced non-small cell lung cancer. This includes testing Cemiplimab alone or with chemotherapy.

Non-small Cell Lung Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Kidney Transplant: Mannitol vs. Normal Saline

We are studying whether mannitol can help improve kidney transplant outcomes by reducing delayed graft function and early rejections. This trial involves both kidney donors and recipients.

End-Stage Renal Disease>2 yearsMonitoring phase (IV)Standard MedicinesNephrologyUrology

Insulin Eye Drops for Persistent Corneal Epithelial Defects

We are studying whether insulin eye drops can help heal persistent corneal defects better than standard treatments. This trial will also assess the safety of insulin drops and explore factors that may influence treatment success.

Persistent Corneal Epithelial Defect1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOphthalmology

Triple-Negative Breast Cancer: Dato-DXd Treatment

We are studying a new drug for patients with triple-negative breast cancer and brain metastases to see if it can help shrink tumors and improve survival. The trial also examines safety and quality of life for participants.

Triple Negative Breast Cancer>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesNeurologyOncology

Kidney Protection: Cilastatin vs. Thiosulfate

We are comparing cilastatin and thiosulfate to see which better protects kidneys during surgery with chemotherapy for cancer patients. This study aims to reduce kidney damage after the procedure.

Acute Kidney Injury>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesInternal MedicineNephrologyOncology

Multiple Sclerosis: Ozanimod Treatment Study

We are investigating how ozanimod affects inflammation in the brain and spinal cord for individuals with Multiple Sclerosis. This study aims to understand its potential benefits and any side effects.

Relapsing Multiple Sclerosis>2 yearsMonitoring phase (IV)Post-Trial Drug AccessNo PlaceboStandard MedicinesNeurology

HIV Treatment: Venetoclax Study

We are testing the safety of a medication called venetoclax in people living with HIV who are on antiretroviral therapy. The aim is to see if it can help reduce the size of the HIV reservoir in the body.

HIV-1 Disease1-2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesPartially RemoteHematologyInfectious Diseases

Nintedanib for Nosebleeds in Hereditary Hemorrhagic Telangiectasia

We are studying whether nintedanib can help reduce the duration of nosebleeds in patients with hereditary hemorrhagic telangiectasia. The trial also examines its effects on quality of life and potential side effects.

Hereditary Hemorrhagic Telangiectasia1-2 yearsEfficacy phase (II)6-10 visitsStandard MedicinesHematologyInternal Medicine

Neural Stem Cell Treatment for Amyotrophic Lateral Sclerosis

We are studying a new treatment using neural stem cells for people with ALS. The trial aims to assess safety and whether it may help slow disease progression.

Amyotrophic Lateral Sclerosis>2 yearsEfficacy phase (II)6-10 visitsStandard MedicinesNeurology

Vitamin D3 for Healing After Wisdom Tooth Removal

We are studying whether high doses of vitamin D3 can improve soft tissue healing after wisdom tooth extraction. We’ll also look at how it affects inflammation during recovery.

Vitamin D Insufficiency Related to Tooth Extraction1-2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesOrthopedics and TraumatologyOtolaryngologyPediatrics

BCG Vaccine for Radiologically Isolated Syndrome (RIS)

We are studying whether the BCG vaccine can help reduce new brain lesions in people diagnosed with Radiologically Isolated Syndrome. The trial also looks at the safety of the vaccine and other brain changes over time.

Radiologically Isolated Syndrome>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesInfectious DiseasesNeurology

SGLT-2 Inhibitors for Elderly Patients with Type 2 Diabetes

We are comparing different SGLT-2 inhibitors to see which helps elderly patients manage their blood sugar levels safely. The study looks at effectiveness and potential side effects over time.

Type 2 DiabetesMonitoring phase (IV)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesDiabetologyEndocrinology

High Blood Pressure: Metyrapone for Adrenal Tumors

We are studying if adding Metyrapone helps patients with high blood pressure and adrenal tumors manage their condition better. This trial aims to improve blood pressure control in those with subclinical Cushing's syndrome.

Adrenal Incidentalomas and Mild Cushing’s Syndrome>2 yearsMonitoring phase (IV)11-15 visitsNo PlaceboStandard MedicinesCardiologyEndocrinology

Bladder Cancer: New Treatment Combination Study

We are investigating a new treatment combining chemotherapy and immunotherapy with radiotherapy for patients with non-metastatic muscle invasive bladder cancer. The goal is to see if this approach improves survival and quality of life after surgery.

Non-Metastatic Muscle Invasive Bladder Cancer1-2 yearsEfficacy phase (II)16-20 visitsNo PlaceboStandard MedicinesOncologyUrology

Pancreatic Cancer: Nabpaclitaxel Chemotherapy Study

We are studying a new combination of chemotherapy treatments for patients with pancreatic cancer that has spread to the abdominal lining. The goal is to see if this approach can help shrink tumors and improve survival.

Pancreatic Cancer with Peritoneal MetastasesEfficacy phase (II)No PlaceboStandard MedicinesGastroenterologyOncology

Myasthenia Gravis: Rituximab Treatment Study

We are studying whether rituximab can help improve symptoms and quality of life for patients with generalized AChR-antibody positive Myasthenia Gravis. The trial will also assess its safety and impact on other treatments.

Generalized Myasthenia Gravis6-12 monthsConfirmation phase (III)Standard MedicinesNeurologyRheumatology

Cardiac Arrest: Landiolol Treatment Study

We are testing whether adding landiolol can help patients who have had a cardiac arrest regain a stable heartbeat faster. This study will also look at overall survival and safety outcomes.

Cardiac Arrest and Ventricular Fibrillation6-12 monthsEfficacy phase (II)6-10 visitsStandard MedicinesPartially RemoteCardiologyInternal Medicine